Clinical Trial Update: Dosimetry Guided PRRT With 90Y-DOTATOC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating dosimetry-guided peptide receptor radionuclide therapy using 90Y-DOTATOC has been withdrawn. The study covered neuroendocrine tumors,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medulloblastoma
• Meningioma
• Neuroblastoma
• Neuroendocrine Tumors

Drugs mentioned

• 90Y-DOTATOC (DOTATOC)

Snippet

Sponsor: Sue O'Dorisio | Conditions: Neuroendrocrine Tumors, Meningioma | Phase 2 | Status: WITHDRAWN